Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 7,648

(AP) — U.S. health officials Saturday agreed to allow emergency use of a second antibody drug to help the immune system fight COVID-19, an experimental medicine that President Donald Trump was given when he was sickened last month.

The Food and Drug Administration authorized use of the Regeneron Pharmaceuticals Inc. drug to try to prevent hospitalization and worsening disease from developing in patients with mild-to-moderate symptoms.

The drug is given as a one-time treatment through an IV. The FDA allowed its use in adults and children 12 and over who weigh at least 88 pounds (40 kilograms) and who are at high risk of severe illness from COVID-19 because of age or certain other medical conditions.

Read more | >

https://www.forbes.com/sites/johnkoetsier/2020/11/20/this-2-…f7a547a57c to Nate Storey, the future of farms is vertical. It’s also indoors, can be placed anywhere on the planet, is heavily integrated with robots and AI, and produces better fruits and vegetables while using 95% less water and 99% less land.

95% less water. 99% less land. 400X more yield.

Read more | >

Does the real future of Space exploration lie with enlightened private entrepreneurs such as Bezos & Musk or do national agencies still have a part to play? https://www.nytimes.com/2020/10/13/science/

Blue Origin’s New Shepard rocket hasn’t flown space tourists yet, but it has found a business niche with NASA and private science experiments.

Read more | >

A bit of a personal post, but it is very dear to me. Please share to everyone you know (especially to a SpaceX recruiter):

In today’s special video, I talk about why I want to apply to SpaceX as an associate buyer. This job application is very special to me because SpaceX has been my dream company ever since highschool. As such, if you find this video worthy, please share (especially to any SpaceX recruiters).

Discord Link: https://discord.gg/brYJDEr.
Patreon link: https://www.patreon.com/TheFuturistTom.
Please follow our instagram at: https://www.instagram.com/the_futurist_tom.
For business inquires, please contact [email protected]

Read more | >

The work was conducted in the laboratory of Dan Peer, PhD, VP for R&D and Head of the Laboratory of Precision Nanomedicine at the Shmunis School of Biomedicine and Cancer Research at TAU. The research was conducted by Daniel Rosenblum, PhD, together with PhD student Anna Gutkin and colleagues in Peer’s laboratory and other collaborators.

The study “CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy” appears in Science Advances.

“Harnessing CRISPR-Cas9 technology for cancer therapeutics has been hampered by low editing efficiency in tumors and potential toxicity of existing delivery systems. Here, we describe a safe and efficient lipid nanoparticle (LNP) for the delivery of Cas9 mRNA and sgRNAs that use a novel amino-ionizable lipid,” write the investigators.

Read more | >